SCFSkp2-IN-2 NEW
| Price | $38 | $77 | $128 |
| Package | 10mg | 25mg | 50mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: SCFSkp2-IN-2 | CAS No.: 1375060-02-8 |
| Purity: 99.86% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | SCFSkp2-IN-2 |
| Description | SCFSkp2-IN-2, a Skp2 inhibitor, exhibits a dissociation constant (K_D) of 28.77 μM. It demonstrates antitumor activities by inducing apoptosis in non-small cell lung cancer (NSCLC) cells. |
| In vitro | SCFSkp2-IN-2 (Compound AAA-237) (0.3-3 μM; 24-72 h) binds directly to Skp2, leading to its proteasome-mediated degradation without affecting Skp2 mRNA expression but inhibiting Skp2 protein expression in a time-dependent manner in NSCLC cells. SCFSkp2-IN-2 inhibits the proliferation of A549 and H1299 cells and induces apoptosis in a dose- and time-dependent manner, blocks the cell cycle at the G0/G1 checkpoint by regulating the Skp2-Cip/Kip and PI3K/Akt-FOXO1 signaling pathways, and induces NSCLC cell senescence (0.3 μM; 1-7 days).[1] |
| In vivo | SCFSkp2-IN-2 (Compound AAA-237) administered at 15 or 45 mg/kg intraperitoneally on a daily basis for 14 days demonstrated antitumor activity in an A549 lung cancer xenograft mouse model.[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 112.5 mg/mL (360.15 mM), Sonication and heating to 60℃ are recommended. |
| Keywords | Skp2 | SCFSkp2-IN-2 | SCFSkp2IN2 | E3Enzyme | E3 Enzyme | E2Enzyme | E2 Enzyme | E1Enzyme | E1/E2/E3 Enzyme | E1 Enzyme | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Multi-Target Compound Library | Post-Translational Modification Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2820.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-07-14 | |
| $98.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-07-14 | |
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-06-30 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY